Published in Proc Natl Acad Sci U S A on September 12, 2003
Links between mutant p53 and genomic instability. J Cell Biochem (2012) 1.41
Genome-wide array comparative genomic hybridization analysis reveals distinct amplifications in osteosarcoma. BMC Cancer (2004) 1.40
The genetics of osteosarcoma. Sarcoma (2012) 1.33
MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate with p53 deficiency in mouse osteosarcoma progression. Cancer Res (2009) 1.30
A Sleeping Beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis. Nat Genet (2015) 1.23
Cell cycle regulator gene CDC5L, a potential target for 6p12-p21 amplicon in osteosarcoma. Mol Cancer Res (2008) 1.16
Exomic analysis of myxoid liposarcomas, synovial sarcomas, and osteosarcomas. Genes Chromosomes Cancer (2013) 1.12
Genetically transforming human mesenchymal stem cells to sarcomas: changes in cellular phenotype and multilineage differentiation potential. Cancer (2009) 1.08
A new approach for prediction of tumor sensitivity to targeted drugs based on functional data. BMC Bioinformatics (2013) 1.05
Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer (2012) 1.03
MicroRNAs and Potential Targets in Osteosarcoma: Review. Front Pediatr (2015) 0.98
Modulation of the E2F1-driven cancer cell fate by the DNA damage response machinery and potential novel E2F1 targets in osteosarcomas. Am J Pathol (2009) 0.97
TP53 mutational status is a potential marker for risk stratification in Wilms tumour with diffuse anaplasia. PLoS One (2014) 0.97
Genetically engineered mouse models and human osteosarcoma. Clin Sarcoma Res (2012) 0.96
Mammalian Exo1 encodes both structural and catalytic functions that play distinct roles in essential biological processes. Proc Natl Acad Sci U S A (2013) 0.95
Decitabine-induced demethylation of 5' CpG island in GADD45A leads to apoptosis in osteosarcoma cells. Neoplasia (2008) 0.95
Array-based comparative genomic hybridization for genomic-wide screening of DNA copy number alterations in aggressive bone tumors. J Exp Clin Cancer Res (2012) 0.92
Animal models in osteosarcoma. Front Oncol (2014) 0.91
Establishment of a new human osteosarcoma cell line, UTOS-1: cytogenetic characterization by array comparative genomic hybridization. J Exp Clin Cancer Res (2009) 0.88
Cis lethal genetic interactions attenuate and alter p53 tumorigenesis. Proc Natl Acad Sci U S A (2010) 0.88
The expression and significance of IDH1 and p53 in osteosarcoma. J Exp Clin Cancer Res (2010) 0.86
Unscrambling the genomic chaos of osteosarcoma reveals extensive transcript fusion, recurrent rearrangements and frequent novel TP53 aberrations. Oncotarget (2016) 0.82
Targeting the p53 Pathway in Ewing Sarcoma. Sarcoma (2010) 0.82
Gain of function mutant p53 proteins cooperate with E2F4 to transcriptionally downregulate RAD17 and BRCA1 gene expression. Oncotarget (2015) 0.82
Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies. Stem Cells Int (2016) 0.81
P53 is required for Doxorubicin-induced apoptosis via the TGF-beta signaling pathway in osteosarcoma-derived cells. Am J Cancer Res (2015) 0.81
An Old Story Retold: Loss of G1 Control Defines A Distinct Genomic Subtype of Esophageal Squamous Cell Carcinoma. Genomics Proteomics Bioinformatics (2015) 0.80
FOXM1 in sarcoma: role in cell cycle, pluripotency genes and stem cell pathways. Oncotarget (2016) 0.79
Osteosarcoma Overview. Rheumatol Ther (2016) 0.79
Transcriptional Profiling Identifies the Signaling Axes of IGF and Transforming Growth Factor-b as Involved in the Pathogenesis of Osteosarcoma. Clin Orthop Relat Res (2016) 0.79
New small molecules targeting apoptosis and cell viability in osteosarcoma. PLoS One (2015) 0.79
Whole exome sequencing of a single osteosarcoma case--integrative analysis with whole transcriptome RNA-seq data. Hum Genomics (2014) 0.79
Prognostic value of p53 alterations in human osteosarcoma: a meta analysis. Int J Clin Exp Pathol (2014) 0.78
Coexistence of HER2, Ki67, and p53 in Osteosarcoma: A Strong Prognostic Factor. N Am J Med Sci (2016) 0.77
Correlation of transcription of MALAT-1, a novel noncoding RNA, with deregulated expression of tumor suppressor p53 in small DNA tumor virus models. J Cancer Ther (2013) 0.77
Lack of major genome instability in tumors of p53 null rats. PLoS One (2015) 0.77
A porcine model of osteosarcoma. Oncogenesis (2016) 0.76
Identification of transcriptional factors and key genes in primary osteoporosis by DNA microarray. Med Sci Monit (2015) 0.75
Michael Overholtzer: answering existential questions on entosis. J Cell Biol (2011) 0.75
Identifying novel therapeutic agents using xenograft models of pediatric cancer. Cancer Chemother Pharmacol (2016) 0.75
The molecular landscape of extraskeletal osteosarcoma: A clinicopathological and molecular biomarker study. J Pathol Clin Res (2015) 0.75
NRSN2 promotes osteosarcoma cell proliferation and growth through PI3K/Akt/MTOR and Wnt/β-catenin signaling. Am J Cancer Res (2017) 0.75
Mesenchymal stromal cells having inactivated RB1 survive following low irradiation and accumulate damaged DNA: Hints for side effects following radiotherapy. Cell Cycle (2016) 0.75
Osteosarcoma: mouse models, cell of origin and cancer stem cell. Postdoc J (2014) 0.75
Analysis of the molecular mechanism of osteosarcoma using a bioinformatics approach. Oncol Lett (2016) 0.75
Microarray and ChIP-seq data analysis revealed changes in p53-mediated transcriptional regulation in Nutlin-3-treated U2OS cells. Mol Med Rep (2015) 0.75
Long non-coding RNA AK093407 promotes proliferation and inhibits apoptosis of human osteosarcoma cells via STAT3 activation. Am J Cancer Res (2017) 0.75
Parathyroid hormone/parathyroid hormone-related peptide regulate osteosarcoma cell functions: Focus on the extracellular matrix (Review). Oncol Rep (2016) 0.75
Novel siRNA formulation to effectively knockdown mutant p53 in osteosarcoma. PLoS One (2017) 0.75
Surfing the p53 network. Nature (2000) 35.36
p53 mutations in human cancers. Science (1991) 31.96
p53, the cellular gatekeeper for growth and division. Cell (1997) 31.04
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature (1992) 25.54
Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature (1992) 17.40
The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell (1992) 16.53
The p53 tumour suppressor gene. Nature (1991) 14.49
p53: puzzle and paradigm. Genes Dev (1996) 13.16
Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell (1997) 12.41
Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science (1996) 9.48
Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature (1993) 7.90
Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell (1992) 7.06
Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem (2000) 6.92
Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell (1992) 6.03
An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat Genet (2003) 5.82
Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev (2000) 5.04
Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J (1998) 4.98
The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol (2001) 4.83
The MDM2 gene amplification database. Nucleic Acids Res (1998) 4.64
Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat Genet (1994) 3.97
Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene (1990) 3.65
Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J (1998) 3.12
Genomic instability and apoptosis are frequent in p53 deficient young mice. Oncogene (1997) 3.01
Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. Proc Natl Acad Sci U S A (1999) 2.89
mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol (1996) 2.78
Novel approach to quantitative polymerase chain reaction using real-time detection: application to the detection of gene amplification in breast cancer. Int J Cancer (1998) 2.52
The p53 functional circuit. J Cell Sci (2001) 2.46
Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene. Mol Med (1995) 2.44
Enhanced proliferative potential in culture of cells from p53-deficient mice. Oncogene (1993) 2.25
Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene. Oncogene (1994) 1.91
p53 point mutation and survival in colorectal cancer patients. Cancer Res (1995) 1.85
Cell type-specific inhibition of p53-mediated apoptosis by mdm2. EMBO J (1996) 1.82
Molecular cytogenetic characterization of head and neck squamous cell carcinoma and refinement of 3q amplification. Cancer Res (2001) 1.62
Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res (1992) 1.60
Comparative genomic hybridisation. Mol Pathol (1999) 1.56
Allelic imbalances in human bladder cancer: genome-wide detection with high-density single-nucleotide polymorphism arrays. J Natl Cancer Inst (2002) 1.34
Gains and losses of DNA sequences in osteosarcomas by comparative genomic hybridization. Cancer Res (1995) 1.34
DNA substrate dependence of p53-mediated regulation of double-strand break repair. Mol Cell Biol (2002) 1.32
Heterogeneity studies identify a subset of sporadic colorectal cancers without evidence for chromosomal or microsatellite instability. Oncogene (1999) 1.32
Homologous and nonhomologous recombination resulting in deletion: effects of p53 status, microhomology, and repetitive DNA length and orientation. Mol Cell Biol (2000) 1.29
p53 and the Li-Fraumeni syndrome. Cancer Genet Cytogenet (1993) 1.23
Dissociation of p53-mediated suppression of homologous recombination from G1/S cell cycle checkpoint control. Oncogene (2000) 1.18
DNA sequence copy number increase at 8q: a potential new prognostic marker in high-grade osteosarcoma. Int J Cancer (1999) 1.15
Chromosomal regions involved in the pathogenesis of osteosarcomas. Genes Chromosomes Cancer (2000) 1.13
p53 abnormalities and genomic instability in primary human breast carcinomas. Cancer Res (1995) 1.09
Mutation detection in K-ras, BRCA1, BRCA2, and p53 using PCR/LDR and a universal DNA microarray. Ann N Y Acad Sci (2000) 1.08
Dissociation of the recombination control and the sequence-specific transactivation function of P53. Oncogene (1999) 1.07
Mutational spectra and immunohistochemical analyses of p53 in human cancers. Chest (1992) 1.02
Malignant tumors of the osteogenic matrix. Eur J Radiol (1998) 0.97
MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status. Br J Cancer (1995) 0.95
The use of real-time quantitative polymerase chain reaction and comparative genomic hybridization to identify amplification of the REL gene in follicular lymphoma. Br J Haematol (2000) 0.92
A molecular and epidemiological study on bladder cancer: p53 mutations, tobacco smoking, and occupational exposure to asbestos. Cancer Epidemiol Biomarkers Prev (1996) 0.90
Loss of wild-type p53 function is responsible for upregulated homologous recombination in immortal rodent fibroblasts. Int J Radiat Biol (2000) 0.88
p53 mutational spectra are different between squamous-cell carcinomas of the lip and the oral cavity. Int J Cancer (2000) 0.80
Progression in transitional cell carcinoma of the urinary bladder--analysis of Tp53 gene mutations by temperature gradients and sequence in tumor tissues and in cellular urine sediments. Cancer Detect Prev (2000) 0.78
Genomic alterations associated with loss of heterozygosity for TP53 in Li-Fraumeni syndrome fibroblasts. Br J Cancer (2000) 0.77
Stochastic gene expression in a single cell. Science (2002) 34.54
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc Natl Acad Sci U S A (2003) 15.59
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med (2005) 13.40
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A (2007) 11.85
Gene regulation at the single-cell level. Science (2005) 11.52
Intrinsic and extrinsic contributions to stochasticity in gene expression. Proc Natl Acad Sci U S A (2002) 11.46
The p53 pathway: positive and negative feedback loops. Oncogene (2005) 9.75
Dynamics of the p53-Mdm2 feedback loop in individual cells. Nat Genet (2004) 8.30
A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell (2004) 8.18
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer (2006) 7.53
The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci U S A (2005) 7.38
Functional roles for noise in genetic circuits. Nature (2010) 6.96
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res (2006) 6.91
Negative autoregulation speeds the response times of transcription networks. J Mol Biol (2002) 6.32
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med (2010) 6.28
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10
Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res (2013) 6.10
An excitable gene regulatory circuit induces transient cellular differentiation. Nature (2006) 6.03
Combinatorial synthesis of genetic networks. Science (2002) 5.91
Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res (2006) 5.69
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet (2012) 5.64
The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer (2007) 5.28
Tunability and noise dependence in differentiation dynamics. Science (2007) 5.23
Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science (2011) 5.04
Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med (2011) 4.91
Frequency-modulated nuclear localization bursts coordinate gene regulation. Nature (2008) 4.63
Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol (2011) 4.37
The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med (2004) 4.28
Functional copy-number alterations in cancer. PLoS One (2008) 4.27
Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis. Bioinformatics (2009) 4.21
Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn (2005) 4.21
Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res (2011) 4.16
p53 regulates maternal reproduction through LIF. Nature (2007) 4.12
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell (2012) 4.09
The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov (2008) 4.03
WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell (2009) 3.76
Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res (2008) 3.70
Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res (2010) 3.68
Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res (2008) 3.67
Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov (2013) 3.64
Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res (2009) 3.56
The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Res (2007) 3.55
Reconstruction of genetic circuits. Nature (2005) 3.41
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet (2011) 3.41
Biology and therapeutic advances for pediatric osteosarcoma. Oncologist (2004) 3.34
Relationship of gene expression and chromosomal abnormalities in colorectal cancer. Cancer Res (2006) 3.32
Programming gene expression with combinatorial promoters. Mol Syst Biol (2007) 3.29
MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res (2006) 3.26
Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res (2010) 3.24
The regulation of exosome secretion: a novel function of the p53 protein. Cancer Res (2006) 3.22
Dyskeratosis congenita and cancer in mice deficient in ribosomal RNA modification. Science (2003) 3.18
Cis-interactions between Notch and Delta generate mutually exclusive signalling states. Nature (2010) 3.06
Architecture-dependent noise discriminates functionally analogous differentiation circuits. Cell (2009) 3.05
HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov (2012) 3.04
MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets (2005) 3.04
Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer (2010) 2.99
Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency. Nature (2008) 2.95
Suppression of immediate-early viral gene expression by herpesvirus-coded microRNAs: implications for latency. Proc Natl Acad Sci U S A (2008) 2.90
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A (2012) 2.89
Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res (2012) 2.85
Modeling a synthetic multicellular clock: repressilators coupled by quorum sensing. Proc Natl Acad Sci U S A (2004) 2.83
EGFR mutations in small-cell lung cancers in patients who have never smoked. N Engl J Med (2006) 2.83
New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res (2011) 2.74
Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res (2008) 2.71
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol (2008) 2.68
Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. Am J Surg Pathol (2003) 2.67
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med (2013) 2.66
CpG island methylator phenotype associates with low-degree chromosomal abnormalities in colorectal cancer. Clin Cancer Res (2008) 2.65
ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res (2013) 2.65
Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J Clin Oncol (2011) 2.58
Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol (2006) 2.58
Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol (2008) 2.56
The ePetri dish, an on-chip cell imaging platform based on subpixel perspective sweeping microscopy (SPSM). Proc Natl Acad Sci U S A (2011) 2.55
Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res (2012) 2.52
Allele-specific p53 mutant reactivation. Cancer Cell (2012) 2.51
Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet (2009) 2.51
Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma. BMC Syst Biol (2010) 2.49
Regulatory activity revealed by dynamic correlations in gene expression noise. Nat Genet (2008) 2.49
High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. Cancer Res (2007) 2.48
Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res (2008) 2.48
Molecular classification of prostate cancer using curated expression signatures. Proc Natl Acad Sci U S A (2011) 2.46
Increased LIS1 expression affects human and mouse brain development. Nat Genet (2009) 2.45
Using movies to analyse gene circuit dynamics in single cells. Nat Rev Microbiol (2009) 2.44
Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping. J Mol Diagn (2010) 2.44
EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther (2013) 2.43
EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol (2005) 2.37
The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation. J Clin Invest (2009) 2.36
Declining p53 function in the aging process: a possible mechanism for the increased tumor incidence in older populations. Proc Natl Acad Sci U S A (2007) 2.36
Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin Cancer Res (2008) 2.34
Advances in sarcoma genomics and new therapeutic targets. Nat Rev Cancer (2011) 2.34
The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein. Trends Cell Biol (2010) 2.33
Unexpected inheritance: multiple integrations of ancient bornavirus and ebolavirus/marburgvirus sequences in vertebrate genomes. PLoS Pathog (2010) 2.32
A plausible model for the digital response of p53 to DNA damage. Proc Natl Acad Sci U S A (2005) 2.32